老年胶质母细胞瘤的手术治疗:法国神经肿瘤学家协会(ANOCEF)试验
这项随机试验纳入≥70岁、KPS≥50且影像学怀疑可手术胶质母细胞瘤的患者,比较肿瘤切除与仅活检(均后续标准治疗)。107例中101例经组织学确诊可评估,手术组与活检组中位生存无显著差异,但手术组无进展生存期显著延长,生活质量与KPS恶化更少,且未增加死亡或并发症。
要点
- 手术组与活检组中位生存期无显著差异(9.37个月 vs 8.96个月,P=0.36)。
- 手术组无进展生存期显著优于活检组(5.06个月 vs 4.02个月,P=0.034)。
- 手术未增加死亡或并发症,生活质量与KPS恶化较活检组更少。
核心结论
- 作者认为减瘤手术是安全的,与活检相比,在老年新诊断恶性胶质瘤患者中与生活质量及自主性恶化更轻相关,并带来显著但幅度有限的无进展生存期改善。
- 尽管切除未能在老年患者中提供显著生存获益,作者认为风险/获益分析支持在仔细术前老年评估的前提下尝试最佳肿瘤切除。
研究设计与样本
- 随机对照试验,纳入≥70岁、Karnofsky功能状态评分(KPS)≥50且影像学怀疑可手术胶质母细胞瘤(GBM)的患者,随机分配至肿瘤切除组或仅活检组。
- 2008年至2019年共9个中心入组107例,101例经组织学确诊GBM可评估分析(手术组50例,活检组51例)。
- 试验早期(2008-2017年)患者接受标准放疗,2017-2019年替莫唑胺成为标准方案后加用辅助替莫唑胺治疗。
- 主要终点为生存,次要终点包括无进展生存期(PFS)、认知状态(简易精神状态检查)、自主性(KPS)、生活质量(EORTC QLQ-C30和QLQ-BN20)及围手术期并发症与死亡率。
主要发现
- 手术组中位生存期9.37个月 vs 活检组8.96个月,差异无统计学意义(P=0.36);校正HR 0.79(95%CI 0.52-1.21,P=0.28)。
- 手术组PFS 5.06个月 vs 活检组4.02个月(P=0.034);校正HR 0.50(95%CI 0.32-0.78,P=0.002)。
- 观察到手术组生活质量恶化程度及KPS评分演变均优于活检组。
- 手术未与死亡率或并发症增加相关。
临床怎么用
- 作者认为风险/获益分析支持在仔细术前老年评估的前提下尝试最佳肿瘤切除。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of surgery in the treatment of malignant gliomas in the elderly is not settled. The authors conducted a randomized trial that compared tumor resection with biopsy only-both followed by standard therapy-in such patients. METHODS: Patients ≥ 70 years of age with a Karnofsky Performance Scale (KPS) score ≥ 50 and presenting with a radiological suspicion of operable glioblastoma (GBM) were randomly assigned between tumor resection and biopsy groups. Subsequently, they underwent standard radiotherapy during the first years of the trial (2008-2017), with the addition of adjunct therapy with temozolomide when this regimen became standard (2017-2019). The primary endpoint was survival, and secondary endpoints were progression-free survival (PFS), cognitive status (Mini-Mental State Examination), autonomy (KPS), quality of life (European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 and QLQ-BN20), and perioperative morbidity and mortality. RESULTS: Between 2008 and 2019, 107 patients from 9 centers were enrolled in the study; 101 were evaluable for analysis because a GBM was histologically confirmed (50 in the surgery arm and 51 in the biopsy arm). There was no statistically significant difference in median survival between the surgery (9.37 months) and the biopsy (8.96 months, p = 0.36) arms (adjusted HR 0.79, 95% CI 0.52-1.21, p = 0.28). However, the surgery group had an increased PFS (5.06 vs 4.02 months; p = 0.034) (adjusted HR 0.50, 95% CI 0.32-0.78, p = 0.002). Less deterioration of quality of life and KPS score evolution than in the biopsy group was observed. Surgery was not associated with increased mortality or morbidity. CONCLUSIONS: This study suggests that debulking surgery is safe, and-compared to biopsy-is associated with a less severe deterioration of quality of life and autonomy, as well as a significant although modest improvement of PFS in elderly patients suffering from newly diagnosed malignant glioma. Although resection does not provide a significant survival benefit in the elderly, the authors believe that the risk/benefit analysis favors an attempt at optimal tumor resection in this population, provided there is careful preoperative geriatric evaluation. Clinical trial registration no.: NCT02892708 (ClinicalTrials.gov).
引用
- Laigle-Donadey F, Metellus P, Guyotat J, et al. Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial. J Neurosurg. 2022. PMID: 36242578. doi:10.3171/2022.8.JNS221068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。